Targeting the p53 Pathway

Surgical Oncology Clinics of North America

Volumn 22, Issue 4, 2013, Pages 747-764

  Golubovskaya, Vita M ^a,b   Cance, William G ^a,b,c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b CureFAKtor Pharmaceuticals   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Apoptosis; FAK; Mdm 2; P53; Survival

Indexed keywords

3 (4 CHLOROPHENYL) 3 (1 HYDROXYMETHYLCYCLOPROPYLMETHOXY) 2 (4 NITROBENZYL) 2,3 DIHYDROISOINDOL 1 ONE; 4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; ANTINEOPLASTIC AGENT; CELECOXIB; CONTUSUGENE LADENOVEC; DOXORUBICIN; ELLIPTICINE; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; GENDICINE; LONTUCIREV; MI 219; MI 319; MI 43; MI 63; MIRA 3; NSC 319726; NSC 66811; NUTLIN 3; P53 REACTIVATION AND INDUCTION OF MASSIVE APOPTOSIS; PF 562271; PROTEIN MDM2; PROTEIN P53; REACTIVATION OF P53 AND INDUCTION OF TUMOR APOPTOSIS; REACTIVATION OF TRANSCRIPTIONAL RECEPTOR ACTIVITY; SCH 529074; STIMA 1; SULFONAMIDE; TD 665759; TERPHENYL 14; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO TERMINAL SEQUENCE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER PREVENTION; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; COLON ADENOCARCINOMA; COLON CANCER; DNA BINDING MOTIF; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; FEEDBACK SYSTEM; FIBROSARCOMA; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INTERACTION; GENE LOCATION; GENE MUTATION; GENE REPRESSION; GENE SEQUENCE; GLIOBLASTOMA; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; INTESTINE POLYP; LIVER CELL CARCINOMA; LIVER TOXICITY; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MOLECULARLY TARGETED THERAPY; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PANCREAS CANCER; PROLINE RICH PROTEIN DOMAIN; PROMOTER REGION; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; SOLID TUMOR; TRANSACTIVATION; TRANSCRIPTION INITIATION; TUMOR INVASION; TUMOR SUPPRESSOR GENE; UPREGULATION; WILD TYPE;

APOPTOSIS; FAK; MDM-2; P53; SURVIVAL;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84883556393     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2013.06.003     Document Type: Review

References (124)

1. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
2. Farmer G., Bargonetti J., Zhu H., et al. Wild-type p53 activates transcription invitro. Nature 1992, 358:83-86.
3. Golubovskaya V.M., Cance W.G. Focal adhesion kinase and p53 signaling in cancer cells. Int Rev Cytol 2007, 263:103-153.
4. Bouchet B.P., de Fromentel C.C., Puisieux A., et al. p53 as a target for anti-cancer drug development. Crit Rev Oncol Hematol 2006, 58:190-207.
5. Khoury M.P., Bourdon J.C. The isoforms of the p53 protein. Cold Spring Harb Perspect Biol 2010, 2:a000927.
6. Lacroix M., Toillon R.A., Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer 2006, 13:293-325.
7. Yu H., Chen J.K., Feng S., et al. Structural basis for the binding of proline-rich peptides to SH3 domains. Cell 1994, 76:933-945.
8. Edwards S.J., Hananeia L., Eccles M.R., et al. The proline-rich region of mouse p53 influences transactivation and apoptosis but is largely dispensable for these functions. Oncogene 2003, 22:4517-4523.
9. Bergamaschi D., Gasco M., Hiller L., et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003, 3:387-402.
10. Stoklsa T., Golab J. Prospects for p53-based cancer therapy. Acta Biochim Pol 2005, 52:321-328.
11. Levine A.J., Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009, 9:749-758.
12. Baker S.J., Preisinger A.C., Jessup J.M., et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990, 50:7717-7722.
13. Fearon E.R., Vogelstein B. Agenetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
14. Giaccia A.J., Kastan M.B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 1998, 12:2973-2983.
15. Hoffman W.H., Biade S., Zilfou J.T., et al. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. JBiol Chem 2002, 277:3247-3257.
16. Wu Y., Mehew J.W., Heckman C.A., et al. Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 2001, 20:240-251.
17. Taylor W.R., Stark G.R. Regulation of the G2/M transition by p53. Oncogene 2001, 20:1803-1815.
18. Krause K., Wasner M., Reinhard W., et al. The tumour suppressor protein p53 can repress transcription of cyclin B. Nucleic Acids Res 2000, 28:4410-4418.
19. Johnsen J.I., Aurelio O.N., Kwaja Z., et al. p53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest. Int J Cancer 2000, 88:685-691.
20. Murphy M., Hinman A., Levine A.J. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev 1996, 10:2971-2980.
21. Yonish-Rouach E., Resnitzky D., Lotem J., et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991, 352:345-347.
22. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 2003, 10:431-442.
23. Lowe S.W., Ruley H.E., Jacks T., et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993, 74:957-967.
24. Lowe S.W., Jacks T., Housman D.E., et al. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc Natl Acad Sci USA 1994, 91:2026-2030.
25. Fridman J.S., Lowe S.W. Control of apoptosis by p53. Oncogene 2003, 22:9030-9040.
26. Owens L.V., Xu L., Craven R.J., et al. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res 1995, 55:2752-2755.
27. Cance W.G., Golubovskaya V.M. Focal adhesion kinase versus p53: apoptosis or survival?. Sci Signal 2008, 1:pe22.
28. Cance W.G., Harris J.E., Iacocca M.V., et al. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin Cancer Res 2000, 6:2417-2423.
29. Owens L.V., Xu L., Dent G.A., et al. Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Ann Surg Oncol 1996, 3:100-105.
30. Golubovskaya V.M. Targeting focal adhesion kinase in cancer-part I. Anticancer Agents Med Chem 2010, 10:713.
31. Ilic D., Almeida E.A., Schlaepfer D.D., et al. Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis. JCell Biol 1998, 143:547-560.
32. Zhang Y., Lu H., Dazin P., et al. Squamous cell carcinoma cell aggregates escape suspension-induced, p53-mediated anoikis: Fibronectin and integrin {alpha} mediate survival signals through focal adhesion kinase. JBiol Chem 2004, 279:48342-48349.
33. Livasy C.A., Moore D., Cance W.G., et al. Focal adhesion kinase overexpression in endometrial neoplasia. Appl Immunohistochem Mol Morphol 2004, 12:342-345.
34. Golubovskaya V., Kaur A., Cance W. Cloning and characterization of the promoter region of human focal adhesion kinase gene: nuclear factor kappa B and p53 binding sites. Biochim Biophys Acta 2004, 1678:111-125.
35. Wei C.L., Wu Q., Vega V.B., et al. Aglobal map of p53 transcription-factor binding sites in the human genome. Cell 2006, 124:207-219.
36. Golubovskaya V.M., Conway-Dorsey K., Edmiston S.N., et al. FAK overexpression and p53 mutations are highly correlated in human breast cancer. Int J Cancer 2009, 125:1735-1738.
37. Rosado P., Lequerica-Fernandez P., Pena I., et al. In oral squamous cell carcinoma, high FAK expression is correlated with low P53 expression. Virchows Arch 2012, 461:163-168.
38. Golubovskaya V.M., Finch R., Cance W.G. Direct Interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53. JBiol Chem 2005, 280:25008-25021.
39. Stewart A., Ham C., Zachary I. The focal adhesion kinase amino-terminal domain localises to nuclei and intercellular junctions in HEK 293 and MDCK cells independently of tyrosine 397 and the carboxy-terminal domain. Biochem Biophys Res Commun 2002, 299:62-73.
40. Beviglia L., Golubovskaya V., Xu L., et al. Focal adhesion kinase N-terminus in breast carcinoma cells induces rounding, detachment and apoptosis. Biochem J 2003, 373:201-210.
41. Jones G., Stewart G. Nuclear import of N-terminal FAK by activation of the FcepsilonRI receptor in RBL-2H3 cells. Biochem Biophys Res Commun 2004, 314:39-45.
42. Lobo M., Zachary I. Nuclear localization and apoptotic regulation of an amino-terminal domain focal adhesion kinase fragment in endothelial cells. Biochem Biophys Res Commun 2000, 276:1068-1074.
43. Chipuk J.E., Green D.R. Cytoplasmic p53: bax and forward. Cell Cycle 2004, 3:429-431.
44. Golubovskaya V.M., Finch R., Zheng M., et al. The 7-amino-acid site in the proline-rich region of the N-terminal domain of p53 is involved in the interaction with FAK and is critical for p53 functioning. Biochem J 2008, 411:151-160.
45. Golubovskaya V.M., Cance W. Focal adhesion kinase and p53 signal transduction pathways in cancer. Front Biosci 2010, 15:901-912.
46. Lim S.T., Chen X.L., Lim Y., et al. Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell 2008, 29:9-22.
47. Melkoumian Z.K., Peng X., Gan B., et al. Mechanism of cell cycle regulation by FIP200 in human breast cancer cells. Cancer Res 2005, 65:6676-6684.
48. Mitra S.K., Schlaepfer D.D. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006, 18:516-523.
49. Ho B., Olson G., Figel S., et al. Nanog increases Focal Adhesion Kinase (FAK) promoter activity and expression and directly binds to FAK protein to be phosphorylated. JBiol Chem 2012, 287:18656-18673.
50. Lin T., Chao C., Saito S., et al. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol 2005, 7:165-171.
51. Essmann F., Schulze-Osthoff K. Translational approaches targeting the p53 pathway for anti-cancer therapy. Br J Pharmacol 2012, 165:328-344.
52. Shi J., Zheng D. An update on gene therapy in China. Curr Opin Mol Ther 2009, 11:547-553.
53. Yang Z.X., Wang D., Wang G., et al. Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma. JCancer Res Clin Oncol 2010, 136:625-630.
54. Shi L.M., Myers T.G., Fan Y., et al. Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. Mol Pharmacol 1998, 53:241-251.
55. Sugikawa E., Hosoi T., Yazaki N., et al. Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine. Anticancer Res 1999, 19:3099-3108.
56. Foster B.A., Coffey H.A., Morin M.J., et al. Pharmacological rescue of mutant p53 conformation and function. Science 1999, 286:2507-2510.
57. Wang W., Takimoto R., Rastinejad F., et al. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 2003, 23:2171-2181.
58. Takimoto R., Wang W., Dicker D.T., et al. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 2002, 1:47-55.
59. Rippin T.M., Bykov V.J., Freund S.M., et al. Characterization of the p53-rescue drug CP-31398 invitro and in living cells. Oncogene 2002, 21:2119-2129.
60. Rippin T.M., Freund S.M., Veprintsev D.B., et al. Recognition of DNA by p53 core domain and location of intermolecular contacts of cooperative binding. JMol Biol 2002, 319:351-358.
61. Demma M.J., Wong S., Maxwell E., et al. CP-31398 restores DNA-binding activity to mutant p53 invitro but does not affect p53 homologs p63 and p73. JBiol Chem 2004, 279:45887-45896.
62. Tang X., Zhu Y., Han L., et al. CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. JClin Invest 2007, 117:3753-3764.
63. El-Deiry W.S. Targeting mutant p53 shows promise for sunscreens and skin cancer. JClin Invest 2007, 117:3658-3660.
64. Rao C.V., Swamy M.V., Patlolla J.M., et al. Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/+ mice. Cancer Res 2008, 68:7670-7675.
65. Rao C.V., Steele V.E., Swamy M.V., et al. Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats. Cancer Res 2009, 69:8175-8182.
66. Bykov V.J., Issaeva N., Selivanova G., et al. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 2002, 23:2011-2018.
67. Bykov V.J., Zache N., Stridh H., et al. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 2005, 24:3484-3491.
68. Zache N., Lambert J.M., Wiman K.G., et al. PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53. Cell Oncol 2008, 30:411-418.
69. Demma M., Maxwell E., Ramos R., et al. SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53. JBiol Chem 2010, 285:10198-10212.
70. Bykov V.J., Issaeva N., Zache N., et al. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. JBiol Chem 2005, 280:30384-30391.
71. Zache N., Lambert J.M., Rokaeus N., et al. Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol Oncol 2008, 2:70-80.
72. Kravchenko J.E., Ilyinskaya G.V., Komarov P.G., et al. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci USA 2008, 105:6302-6307.
73. Yu X., Vazquez A., Levine A.J., et al. Allele-specific p53 mutant reactivation. Cancer Cell 2012, 21:614-625.
74. Picksley S.M., Vojtesek B., Sparks A., et al. Immunochemical analysis of the interaction of p53 with MDM2; fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 1994, 9:2523-2529.
75. Kussie P.H., Gorina S., Marechal V., et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996, 274:948-953.
76. Freedman D.A., Epstein C.B., Roth J.C., et al. Agenetic approach to mapping the p53 binding site in the MDM2 protein. Mol Med 1997, 3:248-259.
77. Chi S.W., Lee S.H., Kim D.H., et al. Structural details on mdm2-p53 interaction. JBiol Chem 2005, 280:38795-38802.
78. Galatin P.S., Abraham D.J. Anonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells. JMed Chem 2004, 47:4163-4165.
79. Vassilev L.T., Vu B.T., Graves B., et al. Invivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
80. Vassilev L.T. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 2004, 3:419-421.
81. Tovar C., Rosinski J., Filipovic Z., et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 2006, 103:1888-1893.
82. Tovar C., Higgins B., Kolinsky K., et al. MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer. Mol Cancer 2011, 10:49.
83. Barbarotto E., Corallini F., Rimondi E., et al. Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells. JCell Biochem 2008, 104:595-605.
84. Secchiero P., Zerbinati C., Melloni E., et al. The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts. Neoplasia 2007, 9:853-861.
85. Van Maerken T., Ferdinande L., Taildeman J., et al. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. JNatl Cancer Inst 2009, 101:1562-1574.
86. Issaeva N., Bozko P., Enge M., et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004, 10:1321-1328.
87. Saha M.N., Jiang H., Mukai A., et al. RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses. Mol Cancer Ther 2010, 9:3041-3051.
88. Kazemi A., Safa M., Shahbazi A. RITA enhances chemosensivity of pre-B ALL cells to doxorubicin by inducing p53-dependent apoptosis. Hematology 2011, 16:225-231.
89. de Lange J., Ly L.V., Lodder K., et al. Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma. Oncogene 2012, 31:1105-1116.
90. Saha M.N., Jiang H., Yang Y., et al. Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma. PLoS One 2012, 7:e30215.
91. Zhao C.Y., Szekely L., Bao W., et al. Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. Cancer Res 2010, 70:3372-3381.
92. Yin H., Lee G.I., Park H.S., et al. Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction. Angew Chem Int Ed Engl 2005, 44:2704-2707.
93. Grasberger B.L., Lu T., Schubert C., et al. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. JMed Chem 2005, 48:909-912.
94. Koblish H.K., Zhao S., Franks C.F., et al. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation invitro and sensitize tumors to doxorubicin invivo. Mol Cancer Ther 2006, 5:160-169.
95. Lu Y., Nikolovska-Coleska Z., Fang X., et al. Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy. JMed Chem 2006, 49:3759-3762.
96. Ding K., Lu Y., Nikolovska-Coleska Z., et al. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. JMed Chem 2006, 49:3432-3435.
97. Shangary S., Ding K., Qiu S., et al. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol Cancer Ther 2008, 7:1533-1542.
98. Mohammad R.M., Wu J., Azmi A.S., et al. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol Cancer 2009, 8:115.
99. Azmi A.S., Aboukameel A., Banerjee S., et al. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur J Cancer 2010, 46:1122-1131.
100. Hardcastle I.R., Ahmed S.U., Atkins H., et al. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. JMed Chem 2006, 49:6209-6221.
101. Hardcastle I.R., Liu J., Valeur E., et al. Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency. JMed Chem 2011, 54:1233-1243.
102. McLean G.W., Carragher N.O., Avizienyte E., et al. The role of focal-adhesion kinase in cancer-a new therapeutic opportunity. Nat Rev Cancer 2005, 5:505-515.
103. Xu L.H., Yang X., Craven R.J., et al. The COOH-terminal domain of the focal adhesion kinase induces loss of adhesion and cell death in human tumor cells. Cell Growth Differ 1998, 9:999-1005.
104. Smith C.S., Golubovskaya V.M., Peck E., et al. Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines. Melanoma Res 2005, 15:357-362.
105. Golubovskaya V.M., Zheng M., Zhang L., et al. The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis. BMC Cancer 2009, 9:280.
106. Xu L.H., Owens L.V., Sturge G.C., et al. Attenuation of the expression of the focal adhesion kinase induces apoptosis in tumor cells. Cell Growth Differ 1996, 7:413-418.
107. Slack-Davis J.K., Martin K.H., Tilghman R.W., et al. Cellular characterization of a novel focal adhesion kinase inhibitor. JBiol Chem 2007, 282:14845-14852.
108. Roberts W.G., Ung E., Whalen P., et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 2008, 68:1935-1944.
109. Tanjoni I., Walsh C., Uryu S., et al. PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. Cancer Biol Ther 2010, 9:764-777.
110. Golubovskaya V.M., Nyberg C., Zheng M., et al. Asmall molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. JMed Chem 2008, 51:7405-7416.
111. Hochwald S.N., Nyberg C., Zheng M., et al. Anovel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle 2009, 8:2435-2443.
112. Beierle E.A., Ma X., Stewart J., et al. Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma. Cell Cycle 2010, 9:1005-1015.
113. Golubovskaya V.M., Huang G., Ho B., et al. Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide. Mol Cancer Ther 2013, 12:162-172.
114. Heffler M., Golubovskaya V.M., Dunn K.M., et al. Focal Adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy. Cancer Biol Ther 2013, [Epub ahead of print].
115. Golubovskaya V.M., Figel S., Ho B.T., et al. Asmall molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth invivo. Carcinogenesis 2012, 33:1004-1013.
116. Kurenova E.V., Hunt D.L., He D., et al. Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth invivo. JMed Chem 2009, 52:4716-4724.
117. Vassilev L.T. p53 Activation by small molecules: application in oncology. JMed Chem 2005, 48:4491-4499.
118. Golubovskaya V., Palma N.L., Zheng M., et al. Asmall-molecule inhibitor, 5'-o-tritylthymidine, targets FAK And Mdm-2 interaction, and blocks breast and colon tumorigenesis invivo. Anticancer Agents Med Chem 2013, 13:532-545.
119. Golubovskaya V.M., Ho B., Zheng M., et al. Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth. BMC Cancer 2013, 13(1):342.
120. Akhter S.A., Luttrell L.M., Rockman H.A., et al. Targeting the receptor-Gq interface to inhibit invivo pressure overload myocardial hypertrophy. Science 1998, 280:574-577.
121. Aramburu J., Yaffe M.B., Lopez-Rodriguez C., et al. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 1999, 285:2129-2133.
122. May M.J., D'Acquisto F., Madge L.A., et al. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 2000, 289:1550-1554.
123. van Rooij E., Doevendans P.A., de Theije C.C., et al. Requirement of nuclear factor of activated T-cells in calcineurin-mediated cardiomyocyte hypertrophy. JBiol Chem 2002, 277:48617-48626.
124. Cance W.G., Kurenova E., Marlowe T., et al. Disrupting the scaffold to improve focal adhesion kinase-targeting therapeutics. Sci Signaling 2013, 6:pe10.